Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Nov-Dec;24(6):778-83.
doi: 10.1111/j.1399-0012.2009.01194.x.

Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients

Fu L Luan  1 , Eric Langewisch, Akinlolu Ojo
Affiliations
Clinical Trial

Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients

Fu L Luan et al. Clin Transplant. 2010 Nov-Dec.

Abstract

Background: Metabolic syndrome (MS) and new onset diabetes after transplant (NODAT) are common in kidney transplant patients. We studied the relationship between the two conditions and their impact on metabolic and cardiovascular risk profiles.

Methods: All non-diabetic patients transplanted between 1999 and 2005 who were followed up to 2006 were included. MS and NODAT were determined. Kaplan-Meier survival and various regression analyses were performed to determine the clinical correlates for both conditions and their association with various cardiovascular risk factors.

Results: Among 591 patients, 314 (53.1%) had MS and 90 (15.2%) developed NODAT. The two conditions were highly associated with each other as 84 patients with NODAT also had MS (14.2%). Elevated body mass index and fasting glucose levels at transplant were risk factors for both conditions, whereas weight gain after transplant was associated only with MS. African American, old age, and hypertension-related ESRD were risk factors for NODAT. Finally, the presence of MS was associated with reduced kidney function and elevated uric acid levels, whereas the presence of NODAT with elevated pulse pressure.

Conclusions: MS and NODAT are highly prevalent and significantly associated with impaired metabolic and cardiovascular risk profiles. Early identification of such conditions may facilitate targeted therapeutic intervention.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier new onset diabetes after transplant (NODAT)-free survival between patients with and without metabolic syndrome (MS) (A) and association between MS and NODAT (B).
Fig. 2
Fig. 2
Distribution of metabolic syndrome (MS) components between patients with and without new onset diabetes after transplant (NODAT).
See this image and copyright information in PMC

References

    1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595. - PubMed
    1. Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis. 2006;48:134–42. - PubMed
    1. Hjelmesaeth J, Hartmann A, Midtvedt K, et al. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant. 2001;16:1047–52. - PubMed
    1. Kuypers DR, Claes K, Bammens B, Evenepoel P, Vanrenterghem Y. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM) Nephrol Dial Transplant. 2008;23:2033–42. - PubMed
    1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–85. - PubMed

Publication types

LinkOut - more resources